INVESTOR RELATION

1. WE ARE EAGER TO DISCUSS OPENLY WITH YOU

If you are as excited as we are and highly value this investment opportunity in terms of not only high potential return but also high impact you will help to make on public health, please do contact us by: 

Email: Please click here to send us an email

You could also directly contact Dr. Jiasheng (Jason) Song, Vice President (VP) and the Chief Scientific Officer (CSO) of the AhR Pharmaceuticals, Inc. by:

Email: Please click here to send an email to Dr. Song

Phone: (608) 692-4791

Fax: (608) 848-2558

Post Mail:

2. INTELLECTUAL PROPERTY POSTION OF THE COMPANY

2.1. Intellectual Property Owned by the AhR Pharmaceuticals

• A pending US and other countries' patent (International Application No.: PCT/US2010/052729, International Publication No.: WO/2011/053466): ITE for cancer intervention and eradication. The patent covers the use of ITE in cancer therapeutic intervention and eradication. (You could download the published international application of this patent by clicking here instead of exploring the site of WIPO, World Intellectual Property Organization).

2.2. Intellectual Property Owned by the WARF

The intellectual property owned by the Wisconsin Alumni Research Foundation (WARF) , the owner and manager of the intellectual property of University of Wisconsin-Madison, is licensed to the AhR Pharmaceuticals, Inc.

2.2.1. Inventors of the WARF intellectual property

The WARF intellectual property supporting the technology platform of the company was developed by Dr. Jiasheng (Jason) Song (the founder of the company), Dr. Hector F. Deluca, and their colleagues. Since Dr. Song and his colleagues were in the Department of Biochemistry at the University of Wisconsin-Madison when the inventions were made, they are the inventors, but not the owners, of the intellectual property.

2.2.2. Patents in the WARF intellectual property package

• An issued US patent (US 6,916,834 B2): Preparation and uses of an Ah receptor ligand, 2-(1'H-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester. The patent covers therapeutic preparation of the ITE hormone.

• An issued US patent (US 7,002,019 B2): Synthesis of indole thiazole compounds as ligands for the Ah receptor. The patent covers the chemical synthesis of ITE.

• An issued US patent (US 7,241,900 B2): Synthesis of indole thiazole compounds as ligands for the Ah receptor. The patent covers the compound of ITE and its analogs.

• An issued US patent (US 7,419,992 B2): Use of aryl hydrocarbon receptor ligand as a therapeutic intervention in angiogenesis-implicated disorders. The patent covers the use of ITE in therapeutic intervention of angiogenesis implicated disorders.

3. INVESTOR TAX CREDIT PROGRAM OF WISCONSIN

To assist early-stage businesses conducting pre-commercialization activity related to proprietary technologies in their efforts to attract investors, the State of Wisconsin makes state tax credits available to individuals and groups investing in these businesses. In order for investors being able to take the credits, the business they invested in needs to be designated/certified as Qualified New Business Ventures (QNBV) by Wisconsin Department of Commerce.

The AhR Pharmaceuticals, Inc. has been certified by the Wisconsin Department of Commerce as a QNBV (Qualified New Business Venture) for that purpose. To obtain a copy of this certificate, please click here. To view a list of QNBV of Wisconsin, please click this. For more information about this wonderful program and, importantly, what the Department of Commerce would NOT endorse in relation to this certification, please visit the Wisconsin Department of Commerce website.

4. EXECUTIVE SUMMARY OF THE AhR PHARMA

An executive summary of the company is available for you to download. Please click here to get the condensed version of our business plan. If you would like to have more detailed information, please do not hesitate to contact us. We will be very happy to talk to you.